Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 5

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 5
---
Use of Proceeds

The Issuer expects the net proceeds to it from this offering will be approximately $ billion (after deducting underwriting discounts and its estimated offering expenses). The Issuer intends to use the net proceeds from the sale of the Notes, together with cash on hand, (a) to repurchase, redeem, satisfy and discharge, defease, make a tender offer for, or otherwise repay at maturity (i) all of its 3.600% senior notes due 2025, which have a stated maturity date of

<div align='center'>S-3</div>

TABLE OF CONTENTS

May 14, 2025, in an aggregate outstanding principal amount of $3.750 billion, and/or (ii) all of its 3.800% senior notes due 2025, which have a stated maturity date of March 15, 2025, in an aggregate outstanding principal amount of $2.890 billion, and/or (iii) all of the 3.800% senior notes due 2025 of Allergan Funding SCS (formerly known as Actavis Funding SCS), which have a stated maturity date of March 15, 2025, in an aggregate principal amount of $130.225 million, and, in each case, to pay any premium and accrued and unpaid interest in respect thereof, and/or (b) for general corporate purposes.

Certain Covenants

The indenture governing the Notes includes covenants that, among other things, limit the ability of the Issuer and its subsidiaries to create or permit to exist mortgages with respect to their principal domestic properties and certain other assets and to enter into sale and leaseback transactions with respect to such principal domestic properties and limit the Issuer’s ability to consolidate with or merge into any other entity or convey, transfer, or lease the Issuer’s properties and assets substantially as an entirety. These covenants are subject to a number of important qualifications and limitations. See “ Description of Notes .”

Trustee

U.S. Bank Trust Company, National Association (in its capacity as trustee, the “ Trustee ”).

Additional Notes

The Issuer may “re-open” each series of Notes and issue an unlimited principal amount of additional Notes of that series in the future without the consent of the holders.

Form and Denominations

The Notes will be book-entry only and registered in the name of a nominee of The Depository Trust Company (the “ DTC ”). Investors may elect to hold interests in